Healthcare corporatization and anticompetitive concerns continue escalating, as does the boom in non-essential supply chain intermediaries. These “middlemen” are obstructing the path to affordable, high-quality, equitable healthcare, triggering major legislative and policy issues and actions. Efforts to combat perverse incentives that lead to significant and costly over-utilization are underway, and employers and other healthcare purchasers must play a lead role in accelerating action to clear waste from the system.